263712-20-5

Basic information

• Product Name: 1α,3β-bis(tert-butyldimethylsilyloxy)-[22,22,23,23-2H4]-9,10-secocholesta-5,7,10(19)-triene
• Synonyms: 1α,3β-bis(tert-butyldimethylsilyloxy)-[22,22,23,23-2H4]-9,10-secocholesta-5,7,10(19)-triene
• CAS NO: 263712-20-5
• Molecular Weight: 633.139
• Mol File: 263712-20-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1α,3β-bis(tert-butyldimethylsilyloxy)-[22,22,23,23-2H4]-9,10-secocholesta-5,7,10(19)-triene(CAS DataBase Reference)
• NIST Chemistry Reference: 1α,3β-bis(tert-butyldimethylsilyloxy)-[22,22,23,23-2H4]-9,10-secocholesta-5,7,10(19)-triene(263712-20-5)
• EPA Substance Registry System: 1α,3β-bis(tert-butyldimethylsilyloxy)-[22,22,23,23-2H4]-9,10-secocholesta-5,7,10(19)-triene(263712-20-5)

Safety Data

• Hazardous Substances Data: 263712-20-5(Hazardous Substances Data)

Upstream product

• 263712-12-5 (8β)-De-A,B-8-(tert-butyldimethylsilyloxy)-22-cholestyne-24-ol 
• 214777-06-7 (8β)-De-A,B-23,23-dibromo-8-(tert-butyldimethylsilyloxy)-24-norchol-22-ene 
• 263712-14-7 (8β)-De-A,B-22-cholestyne-8-ol 
• 263712-15-8 (8β)-De-A,B-22-cholestyne-8-one 
• 104651-47-0 (S)-2-[(1R,3aR,4S,7aR)-octahydro-4-[(1,1-dimethylethyl)dimethylsilyloxy]-7a-methyl-1H-inden-1-yl]propanal 
• 81522-68-1 [(2Z)-2-[(3S,5R)-3,5-bis(tert-butyldimethylsilanyloxy)-2-methylenecyclohexylidene]ethyl]diphenylphosphine oxide 
• 263712-19-2 De-A,B-[22,22,23,23-2H₄]-8-oxocholestane 

Relevant articles and documents

Synthesis and pharmacokinetics of 1α-hydroxyvitamin D3 tritiated at 22 and 23 positions showing high specific radioactivity

A novel synthesis of a radioactive compound of 1α-hydroxyvitamin D3 (1αOHD3) (1) and its pharmacokinetics are described. Radioactive 1αOHD3 tritiated at 22 and 23 positions ([22,23-3H4]1αOHD3) (5) was prepared via key reactions of the reduction of acetylenic side chain in the ketone (12) with tritium gas in the presence of palladium-charcoal and the subsequent Wittig reaction with the A-ring synthon (16). [22,23-3H4]1αOHD3 (5) showed high specific radioactivity (111.5 Ci/mmol) and was used successfully in pharmacokinetics studies with rats. In the pharmacokinetics studies, the plasma concentration level of the active form of vitamin D3, 1α,25- dihydroxyvitamin D3 [1α,25(OH)2D3], after oral or intravenous administration of [22,23-3H4]1αOHD3 (5), showed longer half-life, lower maximum concentration, and lower area under the curve than those after treatment of 1α,25(OH)2D3 tritiated at 26 and 27 positions (4). These results might suggest a beneficial therapeutic utility of 1αOHD1 (1) over the treatment of 1α,25(OH)2D3 (2).